Key result
Optimization of cardiac drugs, devices, nonpharmacological measures, and opioids may provide symptom benefit for dyspnoea in chronic heart failure, though specific evidence remains limited.
Why the study?
What is the evidence for various management options to improve dyspnoea in patients with chronic heart failure?
What is the evidence for various management options to improve dyspnoea in patients with chronic heart failure?
Optimization of standard heart failure therapies and devices remains the foundation for managing dyspnoea, while specific symptom-directed treatments like opioids and nonpharmacological measures have a small evidence base.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice for dyspnoea in chronic HF; leaves open the need for prospective trials on opioids and devices.
Oxberry et al. (2008) conducted a review in Dyspnoea in chronic heart failure. Management options for dyspnoea (cardiac drugs, devices, nonpharmacological measures, opioids) was evaluated. Optimization of cardiac drugs, devices, nonpharmacological measures, and opioids may provide symptom benefit for dyspnoea in chronic heart failure, though specific evidence remains limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: